UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes $613,000 Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 55,696 shares of the biotechnology company’s stock, valued at approximately $613,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.10% of Astria Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. Bank of New York Mellon Corp raised its holdings in shares of Astria Therapeutics by 6.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 139,071 shares of the biotechnology company’s stock worth $1,266,000 after acquiring an additional 8,965 shares during the last quarter. Panagora Asset Management Inc. raised its stake in shares of Astria Therapeutics by 104.7% in the second quarter. Panagora Asset Management Inc. now owns 30,926 shares of the biotechnology company’s stock worth $281,000 after purchasing an additional 15,816 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Astria Therapeutics by 4.1% in the second quarter. Rhumbline Advisers now owns 65,375 shares of the biotechnology company’s stock valued at $595,000 after purchasing an additional 2,556 shares in the last quarter. Quest Partners LLC lifted its holdings in shares of Astria Therapeutics by 3,310.6% in the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 3,112 shares in the last quarter. Finally, ClariVest Asset Management LLC purchased a new position in shares of Astria Therapeutics during the second quarter valued at approximately $731,000. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Astria Therapeutics Stock Performance

Shares of ATXS stock opened at $9.56 on Friday. The firm has a market cap of $539.51 million, a price-to-earnings ratio of -4.57 and a beta of 0.67. The firm’s 50-day simple moving average is $10.70 and its two-hundred day simple moving average is $10.69. Astria Therapeutics, Inc. has a 52 week low of $5.94 and a 52 week high of $16.90.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on ATXS shares. Oppenheimer increased their price target on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Astria Therapeutics in a report on Tuesday, December 10th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $25.60.

Astria Therapeutics Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.